Case 1: Use of Niraparib in Ovarian Cancer

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023

Clinical Use of Niraparib in Ovarian CancerПодробнее

Clinical Use of Niraparib in Ovarian Cancer

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical OncologistПодробнее

Learn all about PARP inhibitors with Dr Jon Krell, Consultant Medical Oncologist

Case 1: Diagnostic Tissue Testing in Ovarian CancerПодробнее

Case 1: Diagnostic Tissue Testing in Ovarian Cancer

Niraparib Monotherapy in Late-Line Ovarian CancerПодробнее

Niraparib Monotherapy in Late-Line Ovarian Cancer

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian CancerПодробнее

PRIMA: Frontline Niraparib Maintenance Therapy in Ovarian Cancer

Niraparib Maintenance Therapy for Ovarian CancerПодробнее

Niraparib Maintenance Therapy for Ovarian Cancer

Precision Medicine for Ovarian Cancer (2021)Подробнее

Precision Medicine for Ovarian Cancer (2021)

Case 1: Use of Maintenance Therapy in Ovarian CancerПодробнее

Case 1: Use of Maintenance Therapy in Ovarian Cancer

3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot ThickensПодробнее

3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot Thickens

Personalized Dosing of Niraparib in Ovarian CancerПодробнее

Personalized Dosing of Niraparib in Ovarian Cancer

Ovarian Cancer: Optimizing Treatment With NiraparibПодробнее

Ovarian Cancer: Optimizing Treatment With Niraparib

Management of Niraparib Dosing in Ovarian CancerПодробнее

Management of Niraparib Dosing in Ovarian Cancer

Comment: Niraparib for ovarian cancerПодробнее

Comment: Niraparib for ovarian cancer

Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian CancerПодробнее

Efficacy of Niraparib on PFS in Patients With Recurrent Ovarian Cancer

Treating Ovarian Cancer With Niraparib: The NOVA TrialПодробнее

Treating Ovarian Cancer With Niraparib: The NOVA Trial

The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIAПодробнее

The potential of PARP inhibitors in ovarian cancer: PAOLA-1, PRIMA & VELIA

The AVANOVA study: niraparib and bevacizumab for ovarian cancerПодробнее

The AVANOVA study: niraparib and bevacizumab for ovarian cancer

Case 1: Observation Versus Maintenance Therapy in Ovarian CancerПодробнее

Case 1: Observation Versus Maintenance Therapy in Ovarian Cancer

Dr. Pothuri on Patient-Reported Outcomes With Niraparib in Advanced Ovarian CancerПодробнее

Dr. Pothuri on Patient-Reported Outcomes With Niraparib in Advanced Ovarian Cancer

Dr. Chase on Niraparib as Frontline Maintenance Therapy in Ovarian CancerПодробнее

Dr. Chase on Niraparib as Frontline Maintenance Therapy in Ovarian Cancer

Niraparib Shows Positive Data, Requires Different Dosing in Ovarian CancerПодробнее

Niraparib Shows Positive Data, Requires Different Dosing in Ovarian Cancer

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer TranscriptПодробнее

FDA D.I.S.C.O.: Niraparib in Ovarian Cancer Transcript